Posted by Michael Wonder on 21 Jan 2025
Dyne Therapeutics receives FDA fast track designation for DYNE-101 for the treatment of myotonic dystrophy type 1
21 January 2025 - Dyne Therapeutics today announced that the US FDA has granted fast track designation for DYNE-101 for the treatment of myotonic dystrophy type 1.
DYNE-101 is currently being evaluated in the on-going Phase 1/2 ACHIEVE global clinical trial.
